Skip to main content
. 2018 Aug 30;8(8):e023605. doi: 10.1136/bmjopen-2018-023605

Table 2.

Review status of new active substances approved 1995–2016

Year Number of new active substances approved Number (%) with standard review Number (%) with priority review Number (%) with NOC/c review Number (%) with any expedited pathway review
1995 30 26 (86.7) 4 (13.3) 4 (13.3)
1996 33 24 (72.7) 9 (27.3) 9 (27.3)
1997 42 34 (81.0) 8 (19.0) 8 (19.0)
1998 30 26 (86.7) 2 (6.7) 2 (6.7) 4 (13.3)
1999 36 24 (66.7) 12 (33.3) 0 (0) 12 (33.3)
2000 26 15 (57.7) 11 (42.3) 0 (0) 11 (42.3)
2001 27 17 (63.0) 9 (33.3) 1 (3.7) 10 (37.0)
2002 24 20 (83.3) 4 (16.7) 0 (0) 4 (16.7)
2003 20 12 (60.0) 8 (40.0) 0 (0) 8 (40.0)
2004 29 19 (65.5) 9 (31.0) 1 (3.4) 10 (34.5)
2005 24 13 (54.2) 10 (41.7) 1 (4.2) 11 (45.8)
2006 23 12 (52.2) 9 (39.1) 2 (8.7) 11 (47.8)
2007 24 14 (58.3) 7 (29.2) 3 (12.5) 10 (41.7)
2008 17 11 (64.7) 2 (11.8) 4 (23.5) 6 (35.3)
2009 27 21 (77.8) 6 (22.2) 0 (0) 6 (22.2)
2010 22 20 (90.9) 2 (9.1) 0 (0) 2 (9.1)
2011 27 21 (77.8) 6 (22.2) 0 (0) 6 (22.2)
2012 23 16 (69.6) 5 (21.7) 2 (8.7) 7 (30.4)
2013 39 28 (71.8) 9 (23.1) 2 (5.1) 11 (28.2)
2014 25 18 (72.0) 6 (24.0) 1 (4.0) 7 (28.0)
2015 37 25 (67.6) 5 (13.5) 7 (18.9) 12 (32.4)
2016 38 21 (55.3) 10 (26.3) 7 (18.4) 17 (44.7)
Total 623 438 (70.3) 152 (24.4) 33 (5.3) 185 (29.7)

NOC/c, Notice of Compliance with conditions.